RCS - Physiomics PLC - Physiomics Awarded New Contract

PhysiomicsAnnouncement

17/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250417:nRSQ3690Fa&default-theme=true

RNS Number : 3690F  Physiomics PLC  17 April 2025

17 April 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Physiomics Awarded New Contract

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce a contract award with
a new UK client.

The project will involve the application of modelling and simulation
techniques to support the development of a first-in-class bifunctional
antibody therapy designed to target multiple solid tumour indiciations. More
specifically, Pharmacokinetic modelling approaches will be utilised to predict
the human PK of the molecule in order to support the client to progress this
new therapy into their first-in-human study. The project is valued at £47,600
and is projected to complete over the next three months.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"We are delighted to be working with this new client and supporting their team
with the development of their exciting new therapy. This new contract also
reflects the progress Physiomics is making in expanding its client base and
supporting the development of wider array of new oncology therapies through
its services".

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFQLLFEZLFBBF